This activity is supported by an unrestricted educational grant from Astellas Pharma US, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc., Pfizer

Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

Sukhmani K. Padda, MD
Stanford Cancer Institute

R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University

Keeping current with emerging targeted therapies for NSCLC can be daunting yet exciting.  There are multiple options for first, second and even third line treatment, which can effectively delay progression or improve overall survival.  This activity provides the AP with a valuable overview and update on NSCLC targeted therapies, molecular testing and recommendations for optimizing patient outcomes with newer emerging treatment options.



 

Download Podcast

  
 
 

Download Transcript

 
 

Download Slides

 
 

Download Slides & Transcripts

  





These CE/CME/CEU accredited activities are jointly provided by

JADPRO Logo    Harborside Press Logo    APSHO Logo    Annenberg Logo
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here